<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-160632</identifier>
<setSpec>1695-4033</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Bone marrow transplant in patients with sickle cell anaemia. Experience in one centre</dc:title>
<dc:description xml:lang="en">Introduction. Sickle cell disease (SCD), despite the improvement in the medical management, is still associated with severe morbidity and decreased survival. Allogenic hematopoietic stem cell transplantation (Allo-HSCT) currently provides the only curative therapy. A report is presented on our experience in children with SCD, who underwent Allo-HSCT in a single centre. Material and method. A single centre descriptive study was conducted on patients with SCD who underwent a bone marrow transplant from an HLA-identical sibling donor between January 2010 and December 2014. Epidemiological, clinical and analytical parameters were collected with a follow-up to December 2015. Data are presented as frequencies, percentages, and medians (range). Results. Allo-HCST was performed in 11 patients (8 males) with a median age of 7 years (2-13), all of them with comorbidity prior to the HCST. A stable graft was achieved in 10 out of 11 patients, 9 of them with complete donor chimerism, and one patient with stable mixed chimerism after 1 year of allo-HSCT. One patient has secondary graft failure with re-appearance of symptoms associated with SCD on day 180. Complications of Allo-HSCT are: arterial hypertension 7/11, acute renal failure 3/11, CMV reactivation 9/11, neurological complications 4/11 (subarachnoid haemorrhage, seizure), and acute graft versus host disease (aGVHD) of the skin 6/11, one of whom developed grade iv intestinal aGVHD, causing his death (day 51). None of the patients developed chronic GVHD. The overall survival and event-free survival was 90.9% and 81.9%, respectively, with a median follow-up of 3.1 (1-5.7) years. Conclusions. Allo-HSCT, the only curative therapy, remains associated with morbidity. There was a transplant related mortality in our study, consistent with multicentre studies (1/11), and with aGVHD being the main cause. Other problems still include graft failure (1/11), and neurological complications (4/11), although the permanent sequelae are mild (AU)</dc:description>
<dc:creator>Bardón Cancho, Eduardo</dc:creator>
<dc:creator>Aguado del Hoyo, Alejandra</dc:creator>
<dc:creator>Pascual, Cristina</dc:creator>
<dc:creator>Pérez-Corral, Ana</dc:creator>
<dc:creator>Beléndez, Cristina</dc:creator>
<dc:creator>Cela, Elena</dc:creator>
<dc:creator>García Morin, Marina</dc:creator>
<dc:creator>Garrido, Carmen</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. La enfermedad de células falciformes (ECF), pese a la mejora en el manejo médico, persiste asociada a morbilidad y a menor supervivencia. El alotrasplante de progenitores hematopoyéticos (alo-TPH) es actualmente la única opción curativa. Describir la evolución clínico-analítica de los pacientes trasplantados en nuestro centro. Material y método. Estudio unicéntrico descriptivo, incluye a pacientes con ECF en los que se realiza alo-TPH de médula ósea de hermano HLA-idéntico desde enero del 2010 hasta diciembre del 2014. Se recogen datos epidemiológicos, clínicos y analíticos con tiempo de seguimiento hasta diciembre del 2015. Los datos se presentan como frecuencias, porcentajes y medianas (rango). Resultados. Se recluta a 11 pacientes (8 varones), mediana de edad: 7 años (2-13), todos ellos con comorbilidad previa al TPH. Se consigue injerto estable en 10/11 pacientes, quimerismo completo en 9/11 y quimerismo mixto estable tras un año del TPH en 1/11. Un paciente presenta fallo secundario de injerto con reaparición de clínica el día +180. Complicaciones post-TPH: complicaciones neurológicas 4/11 pacientes (hemorragia subaracnoidea, crisis), HTA 7/11, fallo renal agudo 3/11, reactivación CMV 9/11, EICHa cutáneo 6/11, uno de ellos desarrolla EICH intestinal grado iv causando su fallecimiento (día +51). Ningún paciente desarrolla EICH crónico. Supervivencia global y libre de eventos a los 3,1 años de seguimiento: 90,9 y 81,9%, respectivamente. Conclusiones. El alo-TPH, única opción curativa, no está exento de morbimortalidad, encontramos un riesgo de muerte similar a otras series (1/11), siendo su primera causa el EICH agudo. Otros problemas son fallo de injerto (1/11) y complicaciones neurológicas (4/11), aunque las secuelas permanentes son leves (AU)</dc:description>
<dc:source>An Pediatr (Barc);86(3): 142-150, mar. 2017. tab, graf, ilus</dc:source>
<dc:identifier>ibc-160632</dc:identifier>
<dc:title xml:lang="es">Trasplante de médula ósea en pacientes con anemia falciforme. Experiencia en un centro</dc:title>
<dc:subject>^d768^s22012</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d55983^s22073</dc:subject>
<dc:subject>^d5009^s22021</dc:subject>
<dc:subject>^d52438</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:subject>^d29431^s22045</dc:subject>
<dc:subject>^d29359^s22045</dc:subject>
<dc:subject>^d29359^s22039</dc:subject>
<dc:type>article</dc:type>
<dc:date>201703</dc:date>
</metadata>
</record>
</ibecs-document>
